Approaches to mitigate the unwanted immunogenicity of therapeutic proteins during drug development

LI Salazar-Fontana, DD Desai, TA Khan, RC Pillutla… - The AAPS journal, 2017 - Springer
All biotherapeutics have the potential to induce an immune response. This immunological
response is complex and, in addition to antibody formation, involves T cell activation and …
被引用次数：37 相关文章

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development

LI Salazar-Fontana, DD Desai, TA Khan, RC Pillutla… - The AAPS Journal, 2017 - infona.pl
All biotherapeutics have the potential to induce an immune response. This immunological
response is complex and, in addition to antibody formation, involves T cell activation and …

[引用][C] Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development

LI Salazar-Fontana, DD Desai, TA Khan, RC Pillutla… - The AAPS Journal, 2017 - cir.nii.ac.jp
Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug
Development | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development

LI Salazar-Fontana, DD Desai, TA Khan… - The AAPS …, 2017 - pubmed.ncbi.nlm.nih.gov
All biotherapeutics have the potential to induce an immune response. This immunological
response is complex and, in addition to antibody formation, involves T cell activation and …

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

LI Salazar-Fontana, DD Desai, TA Khan… - The AAPS …, 2017 - europepmc.org
All biotherapeutics have the potential to induce an immune response. This immunological
response is complex and, in addition to antibody formation, involves T cell activation and …